Last $0.58 USD
Change Today +0.0332 / 6.04%
Volume 6.8K
CLRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 4:30 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

collabrx inc (CLRX) Snapshot

Open
$0.55
Previous Close
$0.55
Day High
$0.67
Day Low
$0.55
52 Week High
12/17/13 - $4.30
52 Week Low
12/16/14 - $0.53
Market Cap
1.7M
Average Volume 10 Days
22.0K
EPS TTM
$-1.96
Shares Outstanding
2.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COLLABRX INC (CLRX)

Related News

No related news articles were found.

collabrx inc (CLRX) Related Businessweek News

No Related Businessweek News Found

collabrx inc (CLRX) Details

CollabRx, Inc. provides cloud-based expert systems to inform healthcare decision-making. The company’s cloud-based expert systems provide clinical knowledge to institutions, physicians, researchers, and patients for genomics-based medicine in cancer. It offers CollabRx Therapy Finder, a series of cancer-specific Web-based system applications that are accessed by physicians and patients. The company was formerly known as Tegal Corporation and changed its name to CollabRx, Inc. in September 2012. CollabRx, Inc. was founded in 1972 and is headquartered in San Francisco, California.

15 Employees
Last Reported Date: 11/18/14
Founded in 1972

collabrx inc (CLRX) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $285.1K
Chair of The Editorial Advisory Board, Editor...
Total Annual Compensation: $139.4K
Chief Operating Officer and Vice President
Total Annual Compensation: $13.8K
Vice President of Business Development and St...
Total Annual Compensation: $182.4K
Consultant and Director
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

collabrx inc (CLRX) Key Developments

CollabRx Announces Receipt Of NASDAQ Notice Of Bid Price Deficiency

CollabRx, Inc. announced that it received a letter from the NASDAQ OMX GROUP (Nasdaq) stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted on the Nasdaq Capital Market under the symbol "CLRX." CollabRx management intends to resolve the situation to allow for continued listing on the Nasdaq Capital Market. CollabRx is provided a grace period of 180-calendar days, or until May 18, 2015, to regain compliance with the minimum bid price requirement. If at any time during the 180-day grace period, the minimum closing bid price per share of the Company's common stock closes at or above $1.00 for a minimum of ten consecutive business days, CLRX will regain compliance and the matter will be closed. In the event the Company does not regain compliance within this grace period, it may be eligible to receive an additional 180-day grace period; provided that CLRX meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provides written notice of its intention to cure the minimum bid price deficiency during the second 180-day grace period, by effecting a reverse stock split, if necessary. If it appears to the Nasdaq staff that the Company will not be able to cure the deficiency or if the Company is not otherwise eligible for the additional grace period, the Company's common stock will be subject to delisting by Nasdaq.

CollabRx, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014; Provides Revenue Guidance for the Full Year of 2015

CollabRx, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, revenue was $176,000 against $251,000 a year ago. Operating loss was $1,039,000 against $872,000 a year ago. Loss before income tax benefit was $1,037,000 against $856,000 a year ago. Loss from continuing operations was $1,016,000 against $836,000 a year ago. Net loss was $1,016,000 against $563,000 a year ago. Basic and diluted net loss per share from continuing operations was $0.35 against $0.43 a year ago. Basic and diluted net loss per share was $0.35 against $0.29 a year ago. For the six months, revenue was $240,000 against $521,000 a year ago. Operating loss was $2,309,000 against $1,582,000 a year ago. Loss before income tax benefit was $2,300,000 against $1,556,000 a year ago. Loss from continuing operations was $2,264,000 against $1,515,000 a year ago. Net loss was $2,264,000 against $1,360,000 a year ago. Basic and diluted net loss per share from continuing operations was $1.01 against $0.78 a year ago. Basic and diluted net loss per share was $1.01 against $0.70 a year ago. The company expects to build revenue primarily through the sale of its content in connection with its Genetic Variant Annotation Service. The company expects its revenue to increase as its customers succeed in launching and growing their test sales into a rapidly growing market. In addition, the company expects to report revenue later 2015 in connection with its revenue-sharing agreement for the CancerRx mobile app, developed and marketed in collaboration with Everyday Health's MedPage Today.

Cartagenia Collaborates with CollabRx

Cartagenia has collaborated with CollabRx. It was reported that the contract has been signed to offer Cartagenia's customers access to CollabRx's treatment information resources and services. The collaboration offers clinical and pathology laboratories that have adopted Cartagenia's Bench for Oncology software platform for their genetic sequencing analysis and reporting workflow, with the option to access to CollabRx's medical and scientific knowledge, which they can integrate with their own proprietary information to draft physician ready reports. According to the terms of the contract, CollabRx's Genetic Variant Annotation (GVA) Service will be made accessible through Cartagenia's Bench for Oncology software platform. Both firms will promote the partnership by cooperating on marketing initiatives to inform customers of the benefits and advantages of the joint use of each company's products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRX:US $0.58 USD +0.0332

CLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRX.
View Industry Companies
 

Industry Analysis

CLRX

Industry Average

Valuation CLRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.3x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLLABRX INC, please visit www.collabrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.